Phase specific health care costs associated with giant cell arteritis in Ontario, Canada
Junek M, Barra L, Kopp A, Felfeli T, Gatley J, Widdifield J. J Rheumatol. 2024; Apr 1 [Epub ahead of print].
Importance — Few interventions are proven to reduce total healthcare costs, and addressing cost-related nonadherence has the potential to do so.
Objective — To determine the effect of eliminating out-of-pocket medication fees on total healthcare costs.
Design, Setting, and Participants — This secondary analysis of a multicenter randomized clinical trial using a prespecified outcome took place across 9 primary care sites in Ontario, Canada (6 in Toronto and 3 in rural areas), where healthcare services are generally publicly funded. Adult patients (≥18 years old) reporting cost-related nonadherence to medicines in the past 12 months were recruited between June 1, 2016, and April 28, 2017, and followed up until April 28, 2020. Data analysis was completed in 2021.
Interventions — Access to a comprehensive list of 128 medicines commonly prescribed in ambulatory care with no out-of-pocket costs for 3 years vs usual medicine access.
Main Outcome and Measures — Total publicly funded healthcare costs over 3 years, including costs of hospitalizations. Healthcare costs were determined using administrative data from Ontario’s single-payer healthcare system, and all costs are reported in Canadian dollars with adjustments for inflation.
Results — A total of 747 participants from 9 primary care sites were included in the analysis (mean [SD] age, 51 [14] years; 421 [56.4%] female). Free medicine distribution was associated with a lower median total healthcare spending over 3 years of $1641 (95% CI, $454-$2792; P = .006). Mean total spending was $4465 (95% CI, −$944 to $9874) lower over the 3-year period.
Conclusions and Relevance — In this secondary analysis of a randomized clinical trial, eliminating out-of-pocket medication expenses for patients with cost-related nonadherence in primary care was associated with lower healthcare spending over 3 years. These findings suggest that eliminating out-of-pocket medication costs for patients could reduce overall costs of healthcare.
Persaud N, Bedard M, Boozary A, Glazier RH, Gomes T, Hwang SW, Jüni P, Law MR, Mamdani M, Manns B, Martin D, Morgan SG, Oh P, Pinto AD, Shah BR, Sullivan F, Umali N, Thorpe KE, Tu K, Wu F, Laupacis A; CLEAN Meds study team. JAMA Health Forum. 2023; 4(5):e231127. Epub 2023 May 26.
The ICES website uses cookies. If that’s okay with you, keep on browsing, or learn more about our Privacy Policy.